Single User License: $2500
Member Price: FREE
Use code SUMMER at checkout for 50% OFF
Already a member? Login to access this report free.
Report Highlights
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology is currently the biggest discovery in life science. As a precise gene editing tool, it has been widely used in many areas with a great potential to treat human diseases. While some CRISPR-based therapeutic studies are moving to clinical trials, CRISPR's therapeutic promise was brought into question when some issues were found that could become major obstacles in moving the great genome editing tools to the clinic.
While many groups are actively resolving these obstacles, the significant challenges to minimize the immunological risks and avoid potential tumorgenicity have received more attention as big concerns for CRISPR-Cas therapeutics advancing toward the clinic. We believe it is timely to summarize and analyze the emerging immunological risk and potential tumorgenicity with the CRISPR-Cas systems, to predict how this exciting genome editing market will affect other related segments of the entire life science market in the next few years. We also hope our opinion could serve as a "crowd crystal" on those discussions in response to the issues, and bring a better market environment for the technology to be sharpened and advanced into clinical applications.
Report Includes
- Detailed understanding of the two major types of adaptive immunity to Cas9 proteins, i.e. humoral immunity and cell-mediated immunity
- Comparison of in vivo and ex vivo CRISPR-Cas9 therapy and discussion about clinical safety and probability to enter human clinical trials
- Coverage of technical areas such as protein engineering and metagenomic analysis as driving forces to new CRISPR-Cas system discovery
- A look into the oncogenic risks by CRISPR-Cas9 genome editing and studies on the development and implementation of genetic systems designed to toggle tumor suppressor genes off and back-on again
Analyst Credentials
Mike Fan is a life science marketing and product management professional with more than 20 years of experience cover multiple biotech R&D areas, as well as life science marketing in both academia and industry. Mike has a broad range of technical skills in chemical and biological area and holds a PhD in Chemical Engineering and a Master of Business Administration focusing on Marketing.
Related Reports
Next-generation Sequencing: Emerging Clinical Applications and Global Markets
The global market for clinical applications of next-generation sequencing is estimated to increase from $21.9 billion in 2023 to reach $52.9 billion by 2028, at a compound annual growth rate (CAGR) of 19.3% from 2023 through 2028.
Induced Pluripotent Stem Cells: Global Markets
The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 and forecast to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 through 2028.
Genome Editing: Technologies and Global Markets
The global genome editing market should reach $12.8 billion by 2027 from $4.3 billion in 2022 at a compound annual growth rate (CAGR) of 24.7% for the forecast period of 2022 to 2027.
Synthetic Biology: Global Markets
The global market for synthetic biology is estimated to increase from $9.5 billion in 2021 to $33.2 billion by 2026, at a compound annual growth rate (CAGR) of 28.4% during the forecast period of 2021-2026.
Recent Reports
Global Single-cell Technologies Market
The global market for single-cell technologies is estimated to increase from $3.6 billion in 2023 to reach $9.2 billion by 2029, at a compound annual growth rate (CAGR) of 17.1% from 2024 through 2029.
Artificial Intelligence (AI) in Life Sciences Market
The global market for artificial intelligence (AI) in life sciences products was valued at $8.0 billion in 2023. The market is estimated to grow from $9.8 billion in 2024 to $33.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.9% from 2024 to 2029.
Global Automated and Closed Cell Therapy Market
The global market for automated and closed cell therapy is expected to grow from $1.8 billion in 2024 and is projected to reach $5.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 23.9% during the forecast period of 2024 to 2029.
Theranostics: Global Markets
The global market for theranostics was valued at $3.7 billion in 2023. The market is expected to grow from $4.3 billion in 2024 to $12.7 billion by the end of 2029, at a compound annual growth rate, or CAGR, of 24.0% from 2024 to 2029.
Cell Therapy Biomanufacturing: Global Markets
The global market for cell therapy biomanufacturing is expected to grow from $9.7 billion in 2024 and is projected to reach $16.7 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.5% during the forecast period of 2024 to 2029.
Top Trending Reports
Life Science Tools and Reagents: Global Markets
The global market for life science tools and reagents, including COVID-19 diagnostics was valued at $59.4 billion in 2023. This market is expected to grow from $53.2 billion in 2024 to reach $66.5 billion by the end of 2029, at a CAGR of 4.6% during the forecast period of 2024-2029.
Wearable Medical Devices: Technologies and Global Markets
The global market for wearable medical devices was valued at $35.6 billion in 2023. This market is estimated to grow from $45.0 billion in 2024 to $151.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 27.5% from 2024 through 2029.
Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets
The global market for radiation therapy products and radiopharmaceuticals is expected to grow from $17.5 billion in 2024 and is projected to reach $31.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 12.3% during the forecast period of 2024 to 2029.
Biodegradable Polymers: Global Markets and Technologies
The global market volumes of biodegradable polymers is expected to grow from 1,286.0 kilotons in 2023 and is projected to reach 4,140.0 kilotons by the end of 2028, at a compound annual growth rate (CAGR) of 26.3% during the forecast period of 2023 to 2028.
Carbon Credits Market: Global Outlook
This report provides an up-to-date analysis of current and future markets for carbon credits and the carbon offsets industry. It presents a thorough and up-to-date global assessment of the market and business of carbon credits. The report also includes a competitive landscape, ESG analysis, and detailed company profiles of leading market players.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More